Inmed PharmaceuticalsINM
13F holders, Q1 2025 (March 31)5holders
1new positions
2sold out
$2.07avg. 13F price*
At the end of Q1 2025, 5 institutions reported holding Inmed Pharmaceuticals Inc. (INM) in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 2 sold out. The largest holders were UBS Group AG ($13K), SBI Securities Co., Ltd. ($621) and AllSquare Wealth Management LLC ($2).
- Company
- Inmed Pharmaceuticals Inc.
- CUSIP
- 457637700
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $621 |
| Exits | 2 | $177K |
All 13F filers, Q4 2024 → Q1 2025: 300 shares bought and 42,763 shares sold, net −42,463 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| UBS Group AG | 0.00% | Reduce -41.3% | 6,106 | $13K |
| SBI Securities Co., Ltd. | 0.00% | New | 300 | $621 |
| AllSquare Wealth Management LLC | 0.00% | No change | 1 | $2 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 1 | $2 |
| Banque Cantonale Vaudoise | 0.00% | — | 6 | $0 |
"% of holder's portfolio" is INM's weight in each manager's 13F, not the share of Inmed Pharmaceuticals Inc. the manager owns.